3´ untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer
Lin Tang,1,* Yunzhao Zhao,2,* Weiwei Nie,1 Zexing Wang,1 Xiaoxiang Guan1
1Department of Medical Oncology, 2Department of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People’s Republic of China
*These authors contributed equally to this work
Background: Prohibitin 3´ untranslated region 1630 C>T (rs6917) polymorphism creates a variant T allele that lacks the antiproliferative activity of the more common functional C allele. Previous studies indicate that women carrying the Prohibitin T allele have an increased susceptibility to breast cancer. However, the role of 1630 C>T polymorphism in mRNA expression of prohibitin and its contribution to carcinogenesis in the breast remains controversial.
Methods: Using mRNA expression data from the HapMap online database, we sought an association between prohibitin 1630 C>T polymorphism and its mRNA expression, then conducted a meta-analysis of prohibitin 1630 C>T polymorphism and risk of breast cancer.
Results: Although no significant association was found between prohibitin 1630 C>T polymorphism and mRNA expression in lymphoblastoid cell lines from the HapMap database (Ptrend = 0.543), the present meta-analysis involving 5072 cases and 4796 controls demonstrated that prohibitin 1630 C>T polymorphism was significantly correlated with breast cancer risk in allele contrast model T versus C (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.01–1.18), the homozygote codominant model TT versus CC (OR 1.47, 95% CI 1.12–1.92), and the recessive model TT versus CC/CT (OR 1.45, 95% CI 1.10–1.89).
Conclusion: Our study indicates that minor allele T of prohibitin 1630 C>T polymorphism is associated with increased susceptibility to breast cancer.
Keywords: prohibitin, breast cancer, genetic, polymorphisms, risk
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]